Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 69-79

  Yan, Ling ^a   Bjork, Per ^b   Butuc, Radu ^a   Gawdzik, Joseph ^a   Earley, Judy ^a   Kim, Gene ^a   Hofmann Bowman, Marion A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Active Biotech Research AB   (Sweden)

Author keywords

Atherosclerosis; Quinoline 3 carboxamides; RAGE; S100 proteins

Indexed keywords

ABR 215757; APOLIPOPROTEIN E; IMMUNOMODULATING AGENT; PROTEIN S 100; PROTEIN S 100A12; UNCLASSIFIED DRUG; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; IN VITRO STUDY; INFLAMMATORY CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SMOOTH MUSCLE FIBER; SURFACE PLASMON RESONANCE; TRANSGENIC MOUSE;

ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CALGRANULIN B; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, ATHEROSCLEROTIC; PROTEIN BINDING; QUINOLINES; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS; S100 PROTEINS; VASCULITIS; ZINC;

EID: 84876808211     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.02.023     Document Type: Article

References (32)

1. Yan S.F., Ramasamy R., Schmidt A.M. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010, 106:842-853.
2. Averill M.M., Kerkhoff C., Bornfeldt K.E. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 2012, 32:223-229.
3. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
4. Vogl T., Tenbrock K., Ludwig S., et al. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007, 13:1042-1049.
5. Rosenberg S., Elashoff M.R., Beineke P., et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med 2010, 153:425-434.
6. Wingrove J.A., Daniels S.E., Sehnert A.J., et al. Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet 2008, 1:31-38.
7. Morrow D.A., Wang Y., Croce K., et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the pravastatin or atorvastatin evaluation and infection therapy: thrombolysis in myocardial infarction (PROVE IT-TIMI 22) trial. Am Heart J 2008, 155:49-55.
8. Altwegg L.A., Neidhart M., Hersberger M., et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 2007, 28:941-948.
9. Burke A.P., Kolodgie F.D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004, 24:1266-1271.
10. Abbas A., Aukrust P., Dahl T.B., et al. High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis. Stroke 2012, 43:1347-1353.
11. Das D., Gawdzik J., Dellefave-Castillo L., et al. S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. J Am Coll Cardiol 2012, 60:775-785.
12. Hofmann Bowman M.A., Gawdzik J., Bukhari U., et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 2011, 31:337-344.
13. Bjork P., Bjork A., Vogl T., et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009, 7:e97.
14. Bengtsson A.A., Sturfelt G., Lood C., et al. Pharmacokinetics, tolerability, and preliminary efficacy of ABR-215757, a new quinoline-3-carboxamide derivative, in murine and human SLE. Arthritis Rheum 2012, 64:1579-1588.
15. Carlsten H., Jonsson C., Bokarewa M., Svensson L., Tarkowski A. The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus. Int Immunopharmacol 2004, 4:1515-1523.
16. Comi G., Jeffery D., Kappos L., et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012, 366:1000-1009.
17. Foell D., Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004, 50:3762-3771.
18. Hofmann Bowman M., Wilk J., Heydemann A., et al. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 2010, 106:145-154.
19. Fuellen G., Nacken W., Sorg C., Kerkhoff C. Computational searches for missing orthologs: the case of S100A12 in mice. OMICS 2004, 8:334-340.
20. Yang Z., Tao T., Raftery M.J., Youssef P., Di Girolamo N., Geczy C.L. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001, 69:986-994.
21. Akirav E.M., Preston-Hurlburt P., Garyu J., et al. RAGE expression in human t cells: a link between environmental factors and adaptive immune responses. PLoS One 2012, 7:e34698.
22. Harja E., Bu D.X., Hudson B.I., et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008, 118:183-194.
23. Sampson B., Fagerhol M.K., Sunderkotter C., et al. Hyperzincaemia and hypercalprotectinaemia: a new disorder of zinc metabolism. Lancet 2002, 360:1742-1745.
24. Croce K., Gao H., Wang Y., et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 2009, 120:427-436.
25. Maiseyeu A, Badgeley MA, Kampfrath T, et al. In vivo targeting of inflammation-associated myeloid-related protein 8/14 via gadolinium immunonanoparticles. Arterioscler Thromb Vasc Biol;32:962-70.
26. Alexander M.R., Moehle C.W., Johnson J.L., et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 2012, 122:70-79.
27. Lunniss C.J., Cooper A.W., Eldred C.D., et al. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Bioorg Med Chem Lett 2009, 19:1380-1385.
28. Tomassoli I., Ismaili L., Pudlo M., et al. Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists. Eur J Med Chem 2011, 46:1-10.
29. Haga H.J., Brun J.G., Berntzen H.B., Cervera R., Khamashta M., Hughes G.R. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus 1993, 2:47-50.
30. Soyfoo M.S., Roth J., Vogl T., Pochet R., Decaux G. Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol 2009, 36:2190-2194.
31. Lood C, Stenstrom M, Tyden H, et al. Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res Ther;13:R60.
32. Cheng P., Corzo C.A., Luetteke N., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008, 205:2235-2249.